key: cord-1039738-c3955inl
authors: Márquez-Salinas, Alejandro; Fermín-Martínez, Carlos A; Antonio-Villa, Neftalí Eduardo; Vargas-Vázquez, Arsenio; C. Guerra, Enrique; Campos-Muñoz, Alejandro; Zavala-Romero, Lilian; Mehta, Roopa; Bahena-López, Jessica Paola; Ortiz-Brizuela, Edgar; González-Lara, María Fernanda; Roman-Montes, Carla M; Martinez-Guerra, Bernardo A; Ponce de Leon, Alfredo; Sifuentes-Osornio, José; Gutiérrez-Robledo, Luis Miguel; Aguilar-Salinas, Carlos A; Bello-Chavolla, Omar Yaxmehen
title: Adaptive metabolic and inflammatory responses identified using accelerated aging metrics are linked to adverse outcomes in severe SARS-CoV-2 infection
date: 2021-03-15
journal: J Gerontol A Biol Sci Med Sci
DOI: 10.1093/gerona/glab078
sha: 6691f67f3dfb169021d49f6a0e5d7a2eed966875
doc_id: 1039738
cord_uid: c3955inl

BACKGROUND: Chronological age (CA) is a predictor of adverse COVID-19 outcomes; however, CA alone does not capture individual responses to SARS-CoV-2 infection. Here, we evaluated the influence of aging metrics PhenoAge and PhenoAgeAccel to predict adverse COVID-19 outcomes. Furthermore, we sought to model adaptive metabolic and inflammatory responses to severe SARS-CoV-2 infection using individual PhenoAge components. METHODS: In this retrospective cohort study, we assessed cases admitted to a COVID-19 reference center in Mexico City. PhenoAge and PhenoAgeAccel were estimated using laboratory values at admission. Cox proportional hazards models were fitted to estimate risk for COVID-19 lethality and adverse outcomes (ICU admission, intubation, or death). To explore reproducible patterns which model adaptive responses to SARS-CoV-2 infection, we used k-means clustering using PhenoAge components. RESULTS: We included 1068 subjects of whom 222 presented critical illness and 218 died. PhenoAge was a better predictor of adverse outcomes and lethality compared to CA and SpO(2) and its predictive capacity was sustained for all age groups. Patients with responses associated to PhenoAgeAccel>0 had higher risk of death and critical illness compared to those with lower values (log-rank p<0.001). Using unsupervised clustering we identified four adaptive responses to SARS-CoV-2 infection: 1) Inflammaging associated with CA, 2) metabolic dysfunction associated with cardio-metabolic comorbidities, 3) unfavorable hematological response, and 4) response associated with favorable outcomes. CONCLUSIONS: Adaptive responses related to accelerated aging metrics are linked to adverse COVID-19 outcomes and have unique and distinguishable features. PhenoAge is a better predictor of adverse outcomes compared to CA.

A c c e p t e d M a n u s c r i p t 3 

Coronavirus disease , caused by SARS-CoV-2 infection, has proven to be a major health concern worldwide. Older chronological age and the presence of chronic comorbidities have been associated with a more severe disease course and increased mortality in COVID-19 [1] [2] [3] . Chronological age (CA) has been shown to be inadequate for resource allocation and risk stratification in the setting of multiple diseases, including COVID- 19; consequently, alternative metrics have emerged to estimate mortality, since aging is recognized to vary across all individual at different rates independent of CA [4] [5] [6] . Recently, new tools have been developed to estimate the aging rate based on biomarkers commonly used in clinical practice and, to date, there is only one study assessing the impact of a biological aging metric on COVID-19 [7] . While there are a wide range of tools which can be used to estimate biological aging, those derived from clinical markers such as PhenoAge and PhenoAgeAccel can be particularly useful as some of the parameters used in their estimation may overlap with those which are altered within pathophysiological processes in COVID-19, particularly inflammatory markers, fasting glucose and serum albumin [8] .

Many of the pathways assessed by PhenoAge have implications in the adaptation to exogenous and endogenous stressors. Hence, we hypothesized that PhenoAge and PhenoAgeAccel might capture adaptive responses to SARS-CoV-2 infection which alter the metabolic dynamic and physiological responses to COVID-19 and may aggravate and intensify inflammation and increase risk for adverse outcomes and lethality [9, 10] . Given the overlapping pathways between PhenoAge, PhenoAgeAccel and the adaptive response to severe SARS-CoV-2 infection, we consider that these metrics in an acute setting might model physiological adaptations to infection. Therefore, we aimed to identify the role of PhenoAge and PhenoAgeAccel as predictors of adverse outcomes and lethality related to beyond CA and its individual components. Furthermore, we sought to apply multivariate A c c e p t e d M a n u s c r i p t 4 clustering techniques to explore the presence of reproducible patterns which model adaptive responses to severe SARS-CoV-2 infection.

We conducted a retrospective study comprising a cohort of hospitalized patients aged ≥18 years recruited from March 16th to August 14th, 2020 with confirmed SARS-CoV-2 infection by RT-qPCR test from nasopharyngeal swabs at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), a COVID-19 reference center in Mexico City. Amongst all evaluated patients within the study period, we only considered patients with complete data to estimate PhenoAge (n=1068). All proceedings were approved by the INCMNSZ Research and Ethics Committee, written informed consent was waived due to the retrospective nature of the study. A complete diagram of study recruitment is presented in

Information collected at the time of triage and emergency department evaluation included demographic variables, medical history of comorbidities including type 2 diabetes (T2D), obesity, chronic obstructive pulmonary disease (COPD), asthma, hypertension, immunosuppression, HIV infection, cardiovascular disease (CVD), chronic kidney disease (CKD), chronic liver disease (CLD), smoking habits and current symptoms, as described elsewhere [11] . Physical examination included weight (in kilograms), height (in meters) and vital signs including oxygen saturation measured by pulse oximetry (SpO 2 ). Baseline testing was performed for complete blood count, basic metabolic panel, liver function tests, 

PhenoAge is a biological age estimation calculated using baseline measures for the following parameters: CA, glucose, albumin, creatinine, alkaline phosphatase (ALP), C-reactive protein (CRP), leucocyte count, lymphocyte percentage, red blood cell distribution width (RDW) and mean corpuscular volume (MCV). PhenoAgeAccel, a calculation obtained by regressing PhenoAge values onto CA using linear regression, provides an unbiased interpretation of the rate of aging independently of CA: A PhenoAgeAccel value of 0 represents a phenotypic age consistent with an individual's CA, while negative and positive values represent the biochemical profile of a chronologically younger and a chronologically older individual, respectively [12, 13] . In the context of SARS-CoV-2 infection, the rate of aging cannot be formally assessed by PhenoAgeAccel due to the underlying acute inflammatory process; therefore, we hypothesized that patients with responses that corresponded to those expected for their CA would have a PhenoAgeAccel ≤0 and those who had a worse response than expected would have a PhenoAgeAccel >0 years.

For the purpose of this study, patients admitted to the intensive care unit (ICU) or who required invasive mechanical ventilation (IMV) were categorized as critical cases and patients who died were termed lethal cases; the rest of inpatients were categorized as severe cases. Our primary outcomes were both death and a composite event of either death, ICU admission or IMV that we termed "adverse outcomes". Attending physicians, based on clinical judgment, determined ICU requirement. Clinical recovery was defined as hospital discharge based on the absence of clinical symptoms requiring inpatient management. 

Descriptive statistics were presented as absolute frequencies and percentages for categorical variables and as mean ± SD or median (IQR) for continuous variables. We performed comparisons of for PhenoAccelAge cut-offs using Student's t-test for symmetric, normally distributed continuous variables or the Mann-Whitney U test otherwise. Multiple-group comparisons were carried out using one-way analysis of variance (ANOVA) or Kruskal-Wallis test with post hoc Tukey or Dunn test, where appropriate. Categorical variables were compared using the chi-square test or the Fisher's exact test for comparison of groups with <5 success counts. Missing data was assumed missing at random and was completed using multiple imputation by chained equations using the mice R package. Statistical significance was set at a two-tailed p-value <0.05; all statistical analyses were conducted using R version 4.0.2.

We evaluated the behavior of PhenoAge and PhenoAgeAccel across comorbidity and severity spectrums by comparing values between severe, critical, and lethal cases and with an increasing number of comorbidities. Additionally, we conducted a sensitivity analysis where we stratified age in <50, 50-70 and >70 years to assess this relationship across different age groups. We also compared characteristics of patients with PhenoAgeAccel≤0 to those with PhenoAgeAccel>0; continuous variables were transformed to approach a symmetric distribution and standardized using z-scores. Furthermore, we performed a survival analysis to assess occurrence of adverse outcomes and lethality alone across subgroups, these results are presented as Kaplan-Meier curves compared with log-rank tests. 

We modeled univariate Cox proportional-hazards regressions to predict the development of adverse outcomes and lethality alone for COVID-19 with SpO 2 , PhenoAge, PhenoAgeAccel and all individual components of PhenoAge. To determine which variables were better predictors compared to CA, we examined the C-statistic and differences in Bayesian Information Criterion (ΔBIC): a positive ΔBIC indicates that the model is a better predictor than CA. For multivariate analyses we fitted Cox regression models assessing the incidence of adverse outcomes or lethality alone for COVID-19: the first model included PhenoAge components which were chosen by minimization of BIC and the second model included only PhenoAgeAccel and CA. All models were further adjusted for sex and comorbidities as a sensitivity analysis due to the reported role of these variables in modifying the risk of developing adverse outcomes in COVID-19 patients [14] . Predictive performance of the individual predictors from these models were evaluated using areas under the receiving operating characteristic curve (AUROC) and clinical decision curves using the pROC and rmda R packages.

To identify different adaptive responses to SARS-CoV-2 infection captured by PhenoAge we carried out an unsupervised k-means clustering analysis. Since not all individual PhenoAge components were associated with outcomes after adjustment for covariates, we decided to perform variable selection to optimize multivariate clustering. Variable selection was performed by regressing individual PhenoAge components to lethality with an Elastic Net Cox penalization parameter using k-fold cross-validation (k=10, α=0.5); z-scores of selected variables were used for k-means clustering using the fpc R package with 100 runs. The optimal number of clusters was determined comparing 30 indices with the NbClust R package and cluster stability was evaluated with the Jaccard similarity index (>0.7) using A c c e p t e d M a n u s c r i p t 8 1,000 bootstrapped samples with the clusterboot R package. The resulting subgroups were extensively characterized by comparing adverse outcomes, comorbidities, symptom presentation, demographic variables, and laboratory measures.

We included 1,068 hospitalized COVID-19 patients with a median age of 53 years (44-63) and a median PhenoAge of 82.4 years (70.5-95.7), whereof 675 (63.2%) were male subjects.

Most patients had at least one comorbidity (73.2%), particularly obesity, hypertension and type 2 diabetes mellitus (T2D). During the follow-up, 628 patients (58.8%) were severe cases, 222 (20.8%) were critical cases and 218 (20.4%) were lethal cases; overall, 440 patients (41.2%) had adverse outcomes for COVID-19 ( Table 1) .

We observed a significant increase in both PhenoAge and PhenoAgeAccel with aggravation of clinical status and this tendency was preserved when stratifying by number of comorbidities and age categories (Figure 1A-D, Supplementary Figure 2) . Overall, we found that a high proportion of critical and lethal cases had elevations in PhenoAge and most of them had PhenoAgeAccel >0 (Figure 1E-F) . Using Cox regression, we found that CRP, lymphocytes percentage, albumin, SpO 2 , PhenoAge and PhenoAgeAccel were better predictors for adverse outcomes compared to CA alone. For lethality, only SpO 2 and PhenoAge were better predictors than CA. (Supplementary Tables 1 and 2) . In multivariate Cox regression models, we found that the model comprising lymphocyte percentage, glucose, CRP and CA was the best to predict adverse outcomes, while the model comprising albumin, creatinine, CRP and CA was the best to predict lethality. Notably, the models including only PhenoAgeAccel and CA had a comparable predictive performance for both adverse outcomes and lethality, even after adjusting for sex and comorbidities (Supplementary Tables 3 

A c c e p t e d M a n u s c r i p t 9 4). When assessing the predictive performance of these selected variables, we found that PhenoAgeAccel had a better performance than CA and PhenoAge for adverse outcomes, while the AUC for PhenoAge was higher in the prediction of lethality (p<0.001). Similar results were displayed in clinical decision curves (Supplementary Figure 3) .

We compared demographic and clinical characteristics between patients with PhenoAgeAccel≤0 or PhenoAgeAccel>0, with the latter indicating a response to stress higher than that expected by CA. Cases with PhenoAgeAccel>0 had higher rates of lethality, ≥1 comorbidity, T2D, early-onset diabetes (T2D diagnosis at ≤40 years), hypertension and immunosuppression; these patients had increased PhenoAge and little differences in CA ( Table 1) . Patients with PhenoAgeAccel>0 presented a more pronounced decline in respiratory and metabolic function, as well as immune dysregulation, as shown by the presence of lower lymphocyte percentage and marked elevations on inflammatory biomarkers such as CRP and fibrinogen. Accordingly, these patients had higher incidence of COVID-19 adverse outcomes and lethality (log-rank p<0.001, Figure 2 ).

Next, we sought to use PhenoAge components under the assumption that it would allow us to identify adaptive responses to severe SARS-CoV-2 infection. We identified that CA, glucose, MCV, RDW, lymphocyte percentage, PCR, albumin and creatinine were the best predictors of mortality and adverse outcomes using Elastic Net Cox regression; using these variables, we identified a stable 4-cluster solution with the k-means clustering algorithm. Cluster 1 was composed of 449 subjects (42.1%), who were predominantly male (69.6%), they had the oldest CA with a median of 61 years, but had a median PhenoAgeAccel of 0.07 years, which means they had a response similar to that expected for their CA, they also had a high incidence of adverse outcomes, ICU admission, IMV requirement and lethality alone, as well years) with a slightly older median CA of 48.0 years compared to cluster 3; the incidence of adverse outcomes was the lowest, with a large proportion of patients experiencing clinical improvement (Figure 3, Supplementary Figure 4) .

Finally, we compared normalized clinical variables and laboratory measures across these subgroups and observed the following patterns (Figure 4) shown by low SpO 2 , PaO 2 /FiO 2 ratio and high respiratory rate at the time of initial evaluation. Cycle threshold (CT) for viral load were higher than Cluster 2 but lower than Clusters 3 and 4. Based on those features, we propose that patients in Cluster 1 show an adaptive response related to inflammaging in accordance with CA. 2) Patients in Cluster 2 had a marked elevation in blood glucose, and triglycerides, as well as an increase in BMI; these patients also had a decline in respiratory function and elevations in pulse pressure, lactate, BUN, and ferritin. We labeled this response as related to metabolic dysfunction, driven by cardio-metabolic comorbidities and, particularly, type 2 diabetes. 3) Patients in Cluster 3 had a pronounced elevation in RDW and decrease in MCV, they also had an increase in platelets and a decrease in creatinine and inflammatory biomarkers; they displayed a decline in respiratory function and a slight elevation of triglycerides and BMI, but not glucose. CT viral load was the highest amongst all subgroups. We labeled this as a response with worsened hematologic markers and a pro-thrombotic profile. 4) Finally, patients in cluster 4 had higher lymphocyte percentage and albumin levels and they showed lower values of leukocytes, CRP and multiple inflammatory biomarkers, they also displayed an enhanced respiratory function and, although they had small increases in BMI and triglycerides, they had a decrease in blood glucose. This adaptive response was related to a less pronounced inflammation compared to what would have been expected given their CA and showed a pattern of clinical resilience.

In this study we observed that PhenoAge is a better predictor for development of adverse outcomes and lethality compared to CA in patients with severe COVID-19. Moreover, patients with PhenoAgeAccel>0 showed higher risk of adverse outcomes and COVID-19 lethality, and had impaired metabolic, respiratory, and immunologic functions. Notably, these trends persisted even after adjusting for sex and comorbidities, two major factors which have A c c e p t e d M a n u s c r i p t 12 been heavily associated with adverse outcomes for COVID-19 [3, [15] [16] [17] . Based on these findings, we hypothesized that PhenoAge components would allow us to distinguish physiological adaptations to severe COVID-19. Using unsupervised clustering, we found that PhenoAge components may help distinguish different subtypes of adaptive responses to SARS-CoV-2 infection, with poorer prognosis linked to inflammaging in accordance to CA and metabolic dysregulation, as has previously been hypothesized [18] . We also characterized an adaptive response cluster prone to impaired hematologic markers with prothrombotic features and a favorable profile of patients with low rates of adverse outcomes.

Our results allow us to position PhenoAge as a metric which characterizes acute adaptations to stress, we also found that PhenoAgeAccel is a metric of favorable or worsened adaptive responses to such acute events independently of CA, which may help the clinician to hasten medical treatment in patients at higher risk.

The process of aging in the immune system is characterized by a progressive impairment of innate and adaptive immune responses upon antigen exposure (immunosenescence) and systemic low-grade chronic inflammation (inflammaging) [19] , both of which have been associated with hindered responses against multiple bacterial and viral infections and which could partly explain the disproportionate effect of SARS-CoV-2 infection with increasing CA [20, 21] . These immunological changes associated to aging and chronic diseases may be a consequence of telomere shortening, damage to the DNA and epigenetic changes in hematopoietic cells [5, 22] . Intrinsic differences in individual responses to SARS-CoV-2 infection could make individuals more susceptible to developing cytokine storms and have hypercoagulable state; in addition, accumulation of senescent (i.e. dysfunctional, nonproliferative) non-lymphoid cells in multiple tissues, particularly in the lung, may further promote inflammation and tissue destruction via NK receptors, in fact, a recent study has found that specific natural killer cell immunotypes may be related to COVID-19 severity A c c e p t e d M a n u s c r i p t 13 [23] . Patients with cardio-metabolic comorbidities, particularly obesity and type 2 diabetes, may have worse proinflammatory and hypercoagulability states, causing further endothelial damage [14, 24, 25] . In our study we observed that older individuals with marked elevations in several inflammatory biomarkers (Cluster 1) and patients with PhenoAgeAccel>0, metabolic dysregulation and a high burden of comorbidities (Cluster 2) had worse respiratory function and the highest rates of adverse outcomes and lethality due to COVID-19; while younger patients and with PhenoAgeAccel≤0 (Cluster 4) had an important improvement in respiratory parameters and a reduction in inflammatory biomarkers compared to the other subgroups. Recent findings identified that adaptive immune responses were not responsible for disease severity and adverse outcomes in patients with COVID-19 [26] . In accordance with our observations, these findings indicate that additional adaptations to SARS-CoV-2 infection including inflammatory, metabolic, respiratory, and hematologic changes could explain heterogeneous risk profiles in COVID-19.

The COVID-19 pandemic has disproportionally affected older adults and patients with underlying chronic comorbidities, with several studies pointing at the relevance of CA and comorbidity for risk stratification of COVID-19 outcomes [3, 6, 27] . Given that age could be a potential confounder, we evaluated the effect of PhenoAgeAccel on adverse outcomes and lethality in SARS-CoV-2 infection and found that this metric was superior to CA in the prediction of adverse outcomes, but not lethality alone. Conversely, PhenoAge was consistently a better predictor for both outcomes of interest; these results suggest that although CA influences disease severity, its use should be accompanied by additional metrics to better reflect heterogeneous risk profiles associated to COVID-19, as previously reported. [15, 28] . To date, only one study by Kuo et al. assessed the relationship between PhenoAge and COVID-19 outcomes using data from the UK Biobank. Authors reported that PhenoAgeAccel estimated 10-14 years prior to SARS-CoV-2 infection was a better predictor A c c e p t e d M a n u s c r i p t 14 of positivity to SARS-CoV-2 or COVID-19 related lethality compared to CA. In contrast, our study evaluates PhenoAge at the time of SARS-CoV-2 infection, which allowed us to capture the heterogeneity of physiological responses to SARS-CoV-2 infection using a metric which was designed to assess biological age; however, with its components being collected during an event of acute stress, PhenoAge and PhenoAgeAccel would not allow to assess an underlying process of accelerated aging. Prior efforts in UK cases characterized symptom clusters in COVID-19, which already reflected the heterogeneity of clinical presentations and responses to SARS-CoV-2 infection [29] .Notably, we identified that cycle threshold was higher (indicating a lower viral load) for adaptive responses associated with better outcomes, which has previously been reported [30] .

Here, we have characterized four adaptive responses to severe COVID-19, with relevant prognostic and pathophysiological implications. Our results contrast with a recent large-scale effort to identify disease phenotypes in COVID-19; here, the authors identified three phenotypes with ranged from younger individuals with mild disease, moderate cases in middle aged subjects and severe cases in older adults [31] . Nevertheless, these differences do not explain increased severity in younger individuals, which we captured as Clusters 2 and 3 in our study. Therefore, our approach also allowed us identify factors beyond CA driving In conclusion, we propose that PhenoAge and PhenoAgeAccel may be better predictors for adverse COVID-19 outcomes and lethality compared to CA given that they likely capture physiological adaptations to acute stress. These associations may contribute to characterize adaptive responses which are altered by underlying processes such as aging and comorbidities, and the physiological reserve in response to severe SARS-CoV-2 infection.

Finally, we propose that clustering of these adaptive responses might aid in understanding pathophysiological processes related to the heterogeneity of severe COVID-19.

M a n u s c r i p t 21 

Factors associated with COVID-19-related death using OpenSAFELY

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

AGS Position Statement: Resource Allocation Strategies and Age-Related Considerations in the COVID-19 Era and Beyond

Longitudinal trajectories, correlations and mortality associations of nine biological ages across 20-years follow-up

Rationing Limited Healthcare Resources in the COVID-19 Era and Beyond: Ethical Considerations Regarding Older Adults

COVID-19 severity is predicted by earlier evidence of accelerated aging

COVID-19 and Crosstalk With the Hallmarks of Aging

An inflammatory cytokine signature predicts COVID-19 severity and survival

From causes of aging to death from COVID-19

Clinical and epidemiological characteristics of patients diagnosed with covid-19 in a tertiary care center in mexico city: a prospective cohort study

An epigenetic biomarker of aging for lifespan and healthspan

A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study

Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico

Unequal impact of structural health determinants and comorbidity on COVID-19 severity and lethality in older Mexican adults: Considerations beyond chronological aging

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China

Aging immunity may exacerbate COVID-19

Inflammaging: a new immune-metabolic viewpoint for age-related diseases

Inflammaging decreases adaptive and innate immune responses in mice and humans

Immunosenescence: Implications for response to infection and vaccination in older people

Stress and immunosenescence: The role of telomerase

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic

Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

A geroscience perspective on COVID-19 mortality

Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app

SARS-CoV-2 viral load predicts COVID-19 mortality

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

COVID-19 and Intrinsic Capacity

Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study

A metabolic handbook for the COVID-19 pandemic

Genetic associations for two biological age measures point to distinct aging phenotypes